Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) for CNY 9.4 million on December 16, 2021. Hengxing Pharmaceutical Technology reported total assets of CNY 25.9 million and total common equity of CNY 15.7 million till September 30, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.42 CNY | +3.24% | +0.57% | +13.32% |
Apr. 19 | Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 10 | Fangsheng Pharma's Factories Pass GMP Inspection | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+13.32% | 755M | |
+23.24% | 44.12B | |
+22.22% | 22.61B | |
+18.29% | 15.11B | |
+14.65% | 13.61B | |
+61.64% | 13.34B | |
-8.98% | 6.94B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+15.65% | 5.75B |
- Stock Market
- Equities
- 603998 Stock
- News Hunan Fangsheng Pharmaceutical Co., Ltd.
- Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 9.4 million.